Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Clinician,Pegylated liposomal doxorubicin,"Ovarian cancer, advanced, epithelial, platinum sensitive/ partially sensitive/ intolerant, third line",Pegylated liposomal doxorubicin (Caelyx),Recommended for decline,Community and Hospital,Oncology Agents and Immunosuppressants
